Three live arguments in biotech that are worth having in public

The central debates are about how much platform optionality to preserve, when to narrow around a lead program, and what evidence threshold deserves clinical acceleration. Those questions are best answered with cash runway, operations, and regulator expectations in the room.

Three questions worth debating:
- when platform narratives help or hurt fundraising
- how much optionality to preserve across early programs
- what evidence threshold justifies faster clinical expansion

Background reading before you take a strong stance:
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.
- NCATS translational science spectrum: ncats.nih.gov/translation/spectrum
Useful for keeping research work tied to concrete translational stages.
- NIH video archive: youtube.com/@NIH/videos
Webinars and talks that help keep the science connected to real public research practice.

When you respond, include the environment you are optimizing for. Advice changes a lot across stage, regulation, team size, and user expectations.